MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MWN-AI** Summary
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology firm dedicated to transforming the landscape of cardiometabolic diseases, has announced its participation in the upcoming Life Sciences Virtual Investor Forum on March 12, 2026. CEO Hyung Heon Kim will lead a fireside chat showcasing the company’s innovative pipeline focused on obesity and metabolic therapies. This interactive online event aims to engage investors, allowing them to pose questions in real-time, while an archived version will be made available for those unable to attend live.
Central to MetaVia's development efforts are two promising therapies: DA-1726, aimed at obesity treatment, and vanoglipel (DA-1241), designed for metabolic dysfunction-associated steatohepatitis (MASH). DA-1726 acts as a dual agonist targeting glucagon-like peptide-1 and glucagon receptors, leveraging the natural gut hormone oxyntomodulin to reduce food intake and enhance energy expenditure. Early Phase 1 trials have shown DA-1726’s potential as a best-in-class option for weight loss and glucose control.
Meanwhile, vanoglipel is a G-protein-coupled receptor 119 agonist that stimulates the release of critical gut peptides, including GLP-1 and GIP. Preliminary studies suggest that vanoglipel positively influences liver health, glucose metabolism, and weight reduction, showcasing its efficacy in addressing issues such as hepatic steatosis and inflammation. A Phase 2a clinical study indicated direct effects on liver function alongside improvements in glucose control.
In addition to the forum, investors can connect with MetaVia’s management through one-on-one meetings. For those keen on learning more about MetaVia's initiatives, further details can be accessed on their official website.
MWN-AI** Analysis
As investors gear up for the Life Sciences Virtual Investor Forum on March 12, 2026, MetaVia Inc. (Nasdaq: MTVA) offers a compelling investment opportunity in the biotechnology space with its innovative approach to addressing obesity and metabolic diseases. The company's lead compound, DA-1726, represents a novel advancement in the treatment of obesity and has exhibited promising results in Phase 1 clinical trials, demonstrating a potential for superior weight loss and glucose control compared to existing therapies.
Investors should consider several key factors before the forum. Firstly, the dual agonist mechanism of DA-1726, targeting both the glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), positions MetaVia at the forefront of metabolic therapy innovation. This attribute not only distinguishes it from competitors but also underscores its best-in-class potential, making it an attractive asset in a burgeoning market projected for exponential growth.
Additionally, the progress of vanoglipel (DA-1241), a GPR119 agonist that has shown efficacy in preclinical studies for liver health and glucose management, further strengthens the investment narrative. The early success in clinical trials combined with its dual-action approach to treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) broadens the company's pipeline appeal.
Investors should actively participate in the fireside chat to gauge insights from CEO Hyung Heon Kim about the company's strategic direction and long-term vision. Given that MetaVia is poised to capture a significant share of the obesity treatment market, monitoring its clinical advancement and regulatory progress will be crucial. As the demand for effective therapies continues to escalate, participating in this virtual forum may present a timely opportunity to engage with one of the industry’s innovative players.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET.
This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the live event on the day of the conference, an archived webcast will also be made available after the event.
It is recommended that investors pre-register using this link and run the online system check to expedite participation and receive event updates.
MetaVia will be available for one-on-one meetings, investors may register using this link. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
SOURCE MetaVia Inc.
FAQ**
Can you elaborate on how DA-1726, as a dual agonist, differentiates itself from other obesity treatments, and what specific outcomes from the Phase 1 trial support MetaVia Inc Com Par $0.001 MTVA’s potential best-in-class position?
What key indicators will MetaVia Inc Com Par $0.001 MTVA use to measure success in the ongoing Phase study of vanoglipel, and how do you plan to address any challenges that arise during this trial?
Given the promising pre-clinical results of vanoglipel, what strategies does MetaVia Inc Com Par $0.001 MTVA have in place to accelerate the transition from clinical trials to potential market entry for this therapy?
How does MetaVia Inc Com Par $0.001 MTVA plan to leverage its innovative pipeline of therapies to compete in the rapidly evolving cardiometabolic disease market, particularly in light of growing competition in obesity treatments?
**MWN-AI FAQ is based on asking OpenAI questions about MetaVia Inc Com Par $0.001 (NASDAQ: MTVA).
NASDAQ: MTVA
MTVA Trading
1.26% G/L:
$1.61 Last:
35,850 Volume:
$1.56 Open:
